Author Archives: Vanda Pinto PhD

Rituximab for AAV Linked to Poor Responses to COVID-19 Vaccines

Treatment with the CD20 inhibitor rituximab is significantly associated with poor antibody responses to COVID-19 vaccines among people with ANCA-associated vasculitis (AAV), a study found. However, the number of antibody-producing B-cells, the rituximab dose, and the timing between last rituximab administration and vaccination were all important factors determining how…

Blood Levels of Proteins Identify Active AAV in Long-term Study

Blood levels of several proteins — CXCL13, interleukins IL-6, IL-8, IL-15, IL-18 binding protein (IL-18BP), matrix metalloproteinase-3 (MMP-3), and erythrocyte sedimentation rate (ESR) — were validated as effective at identifying active ANCA-associated vasculitis (AAV) in a long-term study. The study, “Serum Biomarkers of Disease Activity in Longitudinal Assessment…